Project Grant R01AI198632
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $196,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 6, 2026, with completion targeted for April 30, 2028. The award supports research conducted at Cornell's Ithaca, New York campus to investigate hierarchical control mechanisms within endocrine-mediated gene regulatory...
- Federal Grant Award Summary Cornell University, through its Office of Sponsored Programs, received a $743,943 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 5, 2026 through April 30, 2031. The award supports research on the evolution and engineering of specificity in antimicrobial peptides (AMPs), leveraging the Drosophila melanogaster model system to establish general...
- Federal Grant Award Summary Cornell University, through its Office of Sponsored Programs, received a $591,368 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 11, 2025, with a completion date of July 31, 2030. The award supports fundamental research aimed at understanding the epigenetic regulation of natural killer (NK) cell memory, with particular focus on...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $233,441 Project Grant awarded July 17, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, with a completion date of June 30, 2028, funds research investigating the genetic drivers of CD8+ T cell activation and proliferation. The research leverages the Diversity Outbred (DO) mouse model—a...
- Federal Project Grant Award Summary Cornell University's Office of Sponsored Programs received a $746,602 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2030. The award supports investigator-initiated biomedical research to develop novel therapeutics for tuberculosis (TB) treatment by stimulating bacterial cyclic adenosine monophosphate...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a Project Grant of $238,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 1, 2025, with completion scheduled for August 31, 2027. The research project, titled "Embryonic Origins of T Cells," addresses fundamental gaps in understanding T lymphocyte development and function. The grant...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $2.8M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 4, 2026, with a completion date of January 31, 2030. This research grant funds biomedical investigations into post-transcriptional regulation of pathogenic TH17 (T helper 17) cell function, with particular focus on mechanisms...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $392,714 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2030. The award supports research and development of lipid nanoparticles (LNPs) designed to enhance endosomal escape and reduce reactogenicity—key barriers to effective nucleic acid-lipid...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Cornell University $1,086,266 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 7, 2026, for a five-year project concluding April 30, 2031. This Project Grant supports fundamental research into the mechanism of action of beta-lactam antibiotics (penicillin and related compounds), which are critical antimicrobial agents. The research will employ novel...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Cornell University $219,852 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for exploratory research investigating bacterial endosymbiont accommodation in mucoromycete fungi. The two-year project, initiated May 1, 2026 and concluding April 28, 2028, will test the hypothesis that fungi possess a developmental program for accommodating endosymbiotic bacteria, with research to be...
Cornell University received a $2.61M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 8, 2026 through June 30, 2030. The award supports basic biomedical research investigating the NOX-ATM (NADPH oxidase-ATM kinase) signaling pathway and its role in regulating host-microbe interactions, inflammatory cytokine production, and gut epithelial dynamics. Using Drosophila melanogaster as a model system, the research will characterize how microbial infection triggers stress responses independent of DNA damage, with particular focus on phosphorylation of histone H2A (GH2AV) as a marker of immune activation. The project comprises three specific research aims: (1) determining which microbial characteristics induce ATM pathway activation in gut enterocytes and analyzing how cellular age influences this response; (2) analyzing ATM signaling's impact on inflammatory cytokine production, cell dynamics, and tissue repair using molecular and functional genetics approaches; and (3) investigating how ATM signaling decreases host susceptibility to infection. The research is conducted at Cornell University's Ithaca, New York campus and will generate novel insights into how host cells perceive and respond to microbial threats through stress-activated signaling, with potential implications for understanding infectious disease pathogenesis and developing therapeutic interventions.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.6m | 7/8/26 |